臨床外科76巻2号

2021年02月発行

特集 外科医のための—悪性腫瘍補助療法のすべて 各論

結腸癌の術後補助化学療法：経口フッ化ピリミジン単独療法

著者： 石川敏昭¹

所属機関： ¹東京医科歯科大学大学院総合外科学分野

ページ範囲：P.176 - P.184

【ポイント】
◆Stage Ⅲ結腸癌では，再発低リスク例に対して，患者に応じて経口FP単独療法を選択することは適切な治療の一つである．
◆Stage Ⅱ結腸癌では，再発高リスク例に対する術後補助化学療法が弱く推奨されており，患者負担の少ない経口FP単独療法は選択肢の一つとなる．
◆今後は，低リスクStage Ⅲ結腸癌と高リスクStage Ⅱ結腸癌における経口FP単独療法とCAPOX 3か月療法の使い分けが注目される．

参考文献

1）Lembersky BC, Wieand HS, Petrelli NJ, et al：Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage Ⅱ and Ⅲ carcinoma of the colon：results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24：2059-2064, 2006

2）Shimada Y, Hamaguchi T, Mizusawa J, et al：Randomised phase Ⅲ trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage Ⅲ colorectal cancer who have undergone Japanese D2/D3 lymph node dissection：final results of JCOG0205. Eur J Cancer 50：2231-2240, 2014

3）Twelves C, Wong A, Nowacki MP, et al：Capecitabine as adjuvant treatment for stage Ⅲ colon cancer. N Engl J Med 352：2696-2704, 2005

4）Yoshida M, Ishiguro M, Ikejiri K, et al：S-1 as adjuvant chemotherapy for stage Ⅲ colon cancer：a randomized phase Ⅲ study（ACTS-CC trial）. Ann Oncol 25：1743-1749, 2014

5）大腸癌研究会（編）：大腸癌治療ガイドライン医師用2019年版，金原出版，2019

6）Yoshino T, Yamanaka T, Oki E, et al：Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer The ACHIEVE Phase 3 Randomized Clinical Trial. JAMA Oncol 5：1574-1581, 2019

7）Grothey A, Sobrero AF, Shields AF, et al：Duration of adjuvant chemotherapy for stage Ⅲ colon cancer. N Engl J Med 378：1177-1188, 2018

8）de Gramont A, de Gramont A, Chibaudel B, et al：From chemotherapy to targeted therapy in adjuvant treatment for stage Ⅲ colon cancer. Semin Oncol 38：521-532, 2011

9）Haller DG, Tabernero J, Maroun J, et al：Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage Ⅲ colon cancer. J Clin Oncol 29：1465-1471, 2011

10）Yothers G, O'Connell MJ, Allegra CJ, et al：Oxaliplatin as adjuvant therapy for colon cancer：updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29：3768-3774, 2011

11）André T, Boni C, Navarro M, et al：Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial. J Clin Oncol 27：3109-3116, 2009

12）Kusumoto T, Ishiguro M, Nakatani E, et al：Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial：a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage Ⅲ colon cancer. ESMO Open 3：e000428, 2018 doi：10.1136/esmoopen-2018-000428

13）Hamaguchi T, Shimada Y, Mizusawa J, et al：Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage Ⅲ colorectal cancer（JCOG0910）：an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3：47-56, 2018

14）Sargent DJ, Goldberg RM, Jacobson SD, et al：A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345：1091-1097, 2001

15）Haller DG, O'Connell MJ, Cartwright TH, et al：Impact of age and medical comorbidity on adjuvant treatment outcomes for stage Ⅲ colon cancer：a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 26：715-724, 2015

16）McCleary NJ, Meyerhardt JA, Green E, et al：Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage Ⅱ/Ⅲ Colon Cancer：Findings From the ACCENT Database. J Clin Oncol 31：2600-2606, 2013

17）日本臨床腫瘍学会，日本癌治療学会（編）：高齢者のがん薬物療法ガイドライン，南江堂，2019，pp 25-28

18）QUASAR Collaboration Group；Gray R, Barnwell J, McConkey C, et al：Adjuvant chemotherapy versus observation in patients with colorectal cancer：a randomised study. Lancet 370：2020-2029, 2007

19）Matsuda C, Ishiguro M, Teramukai S, et al：A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafureuracil versus surgery alone in stage Ⅱ colon cancer：SACURA trial. Eur J Cancer 96：54-63, 2018

20）Takahashi T, Sadahiro S, Sakamoto K, et al. A prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage Ⅱ colon cancer with risk factors for recurrence using propensity score-based methods（JFMC46-1201）. Annals of Oncology 31（suppl_4）：S409-S461, 2020

21）Benson AB Ⅲ, Schrag D, Somerfield MR, et al：American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage Ⅱ colon cancer. J Clin Oncol 22：3408-3419, 2004

22）Schmoll HJ, Van Cutsem E, Stein A, et al：ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23：2479-2516, 2012

23）Ueno H, Ishiguro M, Nakatani E, et al：Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage Ⅱ Colon Cancer：Results From the SACURA Trial. Clin Oncol 37：1886-1894, 2019

24）石川敏昭，植竹宏之，石黒めぐみ，他：Stage Ⅱ結腸癌に対する術後補助化学療法の第Ⅲ相試験（SACURA trial）におけるMSIと予後の検討．第72回日本消化器外科学会総会，2017，抄録02-82-13-1

25）Yamazaki K, Yamanaka T, Shiozawa M, et al. Oxaliplatin-Based Adjuvant Chemotherapy Duration（3 vs. 6 Months）for High-Risk Stage Ⅱ Colon Cancer：The Randomized Phase 3 ACHIEVE-2 Trial. Annals of Oncology. Published online 25 October 2020. doi：https://doi.org/10.1016/j.annonc.2020.10.480